Bicyclic heterocycle compounds and their uses in therapy
US-2025296930-A1 · Sep 25, 2025 · US
This page is not indexed by search engines while we improve data quality.
Johnson Christopher Norbert patents
Johnson Christopher Norbert is listed as an inventor on 50 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Johnson Christopher Norbert |
| Total patents | 50 |
| First publication | Apr 16, 2015 |
| Latest publication | Sep 25, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
US-2025092027-A1 · Mar 20, 2025 · US
Bicyclic heterocycle compounds and their uses in therapy
US-12202828-B2 · Jan 21, 2025 · US
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
US-12071429-B2 · Aug 27, 2024 · US
Heterobicyclic compounds for inhibiting the activity of SHP2
US-12037345-B2 · Jul 16, 2024 · US
Bicyclic heterocycle compounds and their uses in therapy
US-2024199607-A1 · Jun 20, 2024 · US
Bicyclic heterocycle compounds and their uses in therapy
US-11866428-B2 · Jan 9, 2024 · US
Bicyclic heterocycle compounds and their uses in therapy
US-2023227450-A1 · Jul 20, 2023 · US
Bicyclic heterocycle compounds and their uses in therapy
US-11643410-B2 · May 9, 2023 · US
Heterobicyclic compounds for inhibiting the activity of shp2
US-2022363693-A1 · Nov 17, 2022 · US
Recent patents
Latest publications not already listed above.
Pharmaceutical compounds
US-11466016-B2 · Oct 11, 2022 · US
Bicyclic heterocycle compounds and their uses in therapy
US-2022204503-A1 · Jun 30, 2022 · US
Pyrazolyl quinoxaline kinase inhibitors
US-2022135544-A1 · May 5, 2022 · US
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
US-2022106287-A1 · Apr 7, 2022 · US
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
US-11261171-B1 · Mar 1, 2022 · US
Bicyclic heterocycle compounds and their uses in therapy
US-11225476-B2 · Jan 18, 2022 · US
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
US-2021276984-A1 · Sep 9, 2021 · US
Bicyclic heterocycle compounds and their uses in therapy
US-2021122749-A1 · Apr 29, 2021 · US
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
US-10981898-B2 · Apr 20, 2021 · US
Pharmaceutical compounds
US-2021107908-A1 · Apr 15, 2021 · US
Bicyclic heterocycle compounds and their uses in therapy
US-2020325134-A1 · Oct 15, 2020 · US
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
US-2020247789-A2 · Aug 6, 2020 · US
Pyrazolyl quinoxaline kinase inhibitors
US-2020131153-A1 · Apr 30, 2020 · US
Bicyclic heterocycle compounds and their uses in therapy
US-10618895-B2 · Apr 14, 2020 · US
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
US-2020079761-A1 · Mar 12, 2020 · US
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
US-10544132-B2 · Jan 28, 2020 · US
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
US-10526311-B2 · Jan 7, 2020 · US
Bicyclic heterocycle compounds and their uses in therapy
US-2019375748-A1 · Dec 12, 2019 · US
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
US-2019055215-A1 · Feb 21, 2019 · US
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
US-2019016708-A1 · Jan 17, 2019 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Astex Therapeutics Ltd | 46 |
| Cancer Research Tech Ltd | 12 |
| Taiho Pharmaceutical Co Ltd | 4 |
| Otsuka Pharma Co Ltd | 4 |
| Woolford Alison Jo-Anne | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 48 |
| A61K31/5377 | 34 |
| C07D413/14 | 32 |
| A61K45/06 | 32 |
| A61P43/00 | 28 |